The Open Targets Blog

OCTOBER 31, 2023

Deanne Taylor , lead Principal Investigator of MTP] In the US, formal clinical trials are required to establish the safety and utility of those treatments in pediatric cancers. Deanne Taylor ] The purpose of the project was to deliver harmonized genomic information to support therapeutic discovery in pediatric cancer. The

Bioinformatics 67

Bioinformatics Engineering Clinical Trials Therapies 67

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. iii Current treatment options have limited efficacy in terms of weight loss or are often associated with adverse events. “We

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

Drug Target Review

MARCH 19, 2024

Our polygenic score will enable the application of these treatments to people that specifically need it through precision medicine by identifying the individual at high genetic risk of low circulating levels of the vitamin. The answer is no because there are both genetic and dietary (environmental) causes for low vitamin A.

Laboratories 106

Laboratories Bioinformatics International Research Laboratories 106

The Open Targets Blog

OCTOBER 24, 2023

Amir Feizi is the Director of Bioinformatics at OMass Therapeutics, a spinout from Professor Dame Carol Robinson’s Laboratory at the University of Oxford. OMass Therapeutics is using a new technology platform to develop treatments for rare immunological and genetic diseases with high unmet patient needs.

Bioinformatics 62

Bioinformatics Packaging Pharmaceutical Companies Pharma Companies 62

Nvidia Developer: Drug Discovery

DECEMBER 19, 2023

HiFi-NN annotates protein sequences with enzyme commission (EC) numbers beating the current bioinformatics tool of choice ( blastp ), as well as other SoTA DL models, including CLEAN , in precision and recall (Table 1). For more information, see the NVIDIA BioNeMo product page.

Science 107

Science Small Molecule Bioinformatics Research 107

The Open Targets Blog

FEBRUARY 29, 2024

  With a background in biochemistry and bioinformatics, Lucy was interested in exploring how bioinformatics was applied to real-world healthcare data. I just graduated with a degree in Bioinformatics, and I was interested to see how the skills I learned could be applied.

International 57

International Bioinformatics RNA Disease 57

DrugBank

JUNE 5, 2023

Chris Klinger, Scientific Support Lead, Bioinformatics LinkedIn It sounds like there was a lot going on at BioIT, what were your highlights? are a potential wealth of data to understand conditions and treatment responses. There were several excellent presentations on how to use AI/ML/data science to advance drug discovery efforts.

Bioinformatics 98

Bioinformatics Clinical Trials Science Drugs 98

Broad Institute

AUGUST 20, 2024

By Allessandra DiCorato August 20, 2024 Credit: Elizabeth Gribkoff, Eric and Wendy Schmidt Center Yue Qin, a postdoctoral fellow in the Eric and Wendy Schmidt Center, wants to create an in silico cell — a computational model scientists can use to study at scale how external influences such as drug treatments affect cells.

Science 69

Science Disease Bioinformatics Treatment 69

Drug Target Review

MAY 27, 2024

What role do ADCs play in Caris’ strategy for targeted cancer therapy, particularly in terms of patient-specific treatment plans? Patient specific treatment plans can be tailored to the cohorts that express the targets including feasibility assessment of combinations of our ADC targets with other lines of therapy.

Clinical Trials 59

Clinical Trials Science Molecular Biology Bioinformatics 59

Broad Institute

JULY 10, 2023

Alicia Martin and attendees of the KEMRI-Wellcome Trust/GINGER Bioinformatics training in Kilifi, Kenya in September 2018. For NeuroGAP, Martin is helping oversee data analysis and has guided the collection of demographic information to inform a study on genetics and linguistic variation.

Disease 98

Disease Bioinformatics Medical Schools Research 98

Broad Institute

AUGUST 4, 2022

This profiling could potentially help more accurately tailor prognosis and treatment of a new patient based on their particular molecular features, getting closer to precision medicine." Beyond genetic sequences, the expression patterns of certain genes further subcategorized CLL and provided valuable prognostic information.

Bioinformatics 52

Bioinformatics Medical Schools Hospitals Treatment 52

Vial

DECEMBER 5, 2023

It has become a fundamental tool for researchers to explore the complexities of genetic information and conduct genetic-informed drug development. Improvements in bioinformatics, robotics, liquid handling, and nucleic acid preparation will continue to transform NGS sequencing methods. Fountzilas et al. Satam et al. Satam et al.

Clinical Trials 52

Clinical Trials Trials RNA Bioinformatics 52

DrugBank

FEBRUARY 12, 2025

This approach capitalizes on prior investments in R&D, mitigates risk by leveraging established safety and pharmacokinetic profiles, and accelerates the delivery of treatments to patients. In Silico Drug Repurposing Advances in bioinformatics and systems biology have fueled the rise of repurposing of in silico drugs.

Cell Based Assays 52

Cell Based Assays Drugs Pharmacokinetics Disease 52

The Pharma Data

DECEMBER 27, 2020

“This acquisition affirms our commitment to bring a new generation of treatments to patients with pulmonary hypertension as quickly as possible,” said Michael Benkowitz , President and Chief Operating Officer of United Therapeutics. IMPORTANT SAFETY INFORMATION FOR TYVASO. About TYVASO ® (treprostinil) Inhalation Solution.

FDA 52

FDA Bioinformatics Disease Production 52

Drug Target Review

SEPTEMBER 26, 2024

While these models present an informed starting point, it’s important to integrate these insights with human expertise to navigate the complexities of drug discovery. This enables us to explore novel drug candidates that could be more effective or have fewer side effects than existing treatments and drugs.

Drugs 65

Drugs Production Research Small Molecule 65

The Pharma Data

JULY 27, 2021

” The acquisition will also add TNB-585, a Phase 1 bispecific T cell-engager for the treatment of metastatic castrate-resistant prostate cancer (mCRPC), and several preclinical oncology pipeline assets with the potential for near-term IND filings. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Production 52

Production Clinical Trials Government Disease 52

The Pharma Data

SEPTEMBER 11, 2021

We have the ability to generate precise antibodies to a diverse range of targets, which together with Boehringer Ingelheim’s strength in drug development capabilities, could mean multiple new, more personalized treatments in the future for patients,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist. About Twist Biopharma.

DNA 52

DNA Bioinformatics Production Engineering 52

The Pharma Data

OCTOBER 27, 2020

Treatment with Tyvaso of up to 12 breaths per session, four times daily, in the INCREASE study was well tolerated and the safety profile was consistent with previous Tyvaso studies and known prostacyclin-related adverse events. As such we expect a delay in the ISR launch until 2021. RESEARCH AND DEVELOPMENT UPDATE.

FDA 40

FDA Production Licensing Licensing 40

The Pharma Data

DECEMBER 8, 2020

9, 2020 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to treprostinil for the treatment of patients with idiopathic pulmonary fibrosis (IPF). IMPORTANT SAFETY INFORMATION FOR TYVASO. SILVER SPRING, Md.

FDA 40

FDA Treatment Drugs FDA Approval 40

The Pharma Data

NOVEMBER 15, 2020

R&D collaboration building on Lead Pharma’s expertise in the discovery, design and optimization of small molecule treatments. “Our ambition is to develop life-changing treatments for patients. For more information visit: www.leadpharma.com. OSS, Netherlands , Nov. About Lead Pharma.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

The Pharma Data

OCTOBER 21, 2020

Treatment with Tyvaso of up to 12 breaths per session, four times daily, was well tolerated. Most treatment-related adverse events were mild to moderate in intensity and included cough, headache, dyspnea, dizziness, nausea, fatigue, and diarrhea, many of which are consistent with the existing Tyvaso label. mL and 168.52

Disease 40

Disease Treatment Therapies Production 40

Drug Target Review

SEPTEMBER 30, 2024

We see this inhibition of Regulatory T cells (Tregs) in all patients, which is something that no previous IL-2 based treatment has been able to achieve. People see it as a challenge because most use computational work to inform their experimental work. Our experiments are designed to serve our computational models.

Bioinformatics 65

Bioinformatics Clinical Trials Clinical Development Treatment 65

The Premier Consulting Blog

JUNE 18, 2023

This has opened new opportunities in pharmaceutical drug development, such as the ability to evaluate large complex databases and to integrate information in useful ways. These data inform the construction of disease mechanistic models used to generate a synthetic control arm for use in the trial.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

The Pharma Data

JANUARY 21, 2021

Through its world-class competitions, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair, the Broadcom MASTERS, and its award-winning magazine, Science News and Science News for Students, Society for Science is committed to inform, educate, and inspire.

Science 40

Science Engineering Molecular Biology Disease 40

Agency IQ

OCTOBER 12, 2023

Joneckis said that CBER has “some limited uses that we have seen in external submissions, mostly in the bioinformatics area,” but not as many as CDER. CBER is also using AI in its internal processes, “mostly for machine learning applications for searching and assimilating information in various areas.”

FDA 40

FDA Clinical Trials International Drugs 40

Codon

AUGUST 27, 2024

These laboratories share data and bioinformatics tools that enabled the early detection of SARS-CoV-2 and monkeypox even before their reference genomes were available. Putting a sequencer in every port, hospital, water treatment plant, or subway station isn’t feasible just yet due to the expense.

DNA 111

DNA Laboratories Hospitals Virus 111

PLOS: DNA Science

MAY 16, 2024

Other genomic databases were retooled for the huge datasets that COVID was generating, such as the Cloud Institute for Microbial Bioinformatics, begun in 2014 and rechristened the COVID-19 Genomics UK Consortium ( COG-UK ). • reveals viral vulnerability to inspire novel treatments. It closed a year ago.

Virus 97

Virus DNA RNA Vaccine 97

The Pharma Data

MAY 22, 2023

The International Pathogen Surveillance Network (IPSN) will provide a platform to connect countries and regions, improving systems for collecting and analyzing samples, using these data to drive public health decision-making, and sharing that information more broadly.

Disease 52

Disease Bioinformatics Virus Vaccine 52

Codon

APRIL 16, 2023

But now, a new paper shows how to sequence up to six plasmids in a single sample, while retaining accurate information, using Bayesian statistics. BMC Bioinformatics. Read Extracellular vesicles engineering by silicates-activated endothelial progenitor cells for myocardial infarction treatment in male mice. McCafferty C.L.

Engineering 52

Engineering DNA RNA Science 52

The Pharma Data

SEPTEMBER 1, 2020

The trial included 2,494 patients who had previously completed a Phase 1, 2 or 3 Zeposia clinical trial and who had an average treatment time of 35.4 Gaining insight into long-term therapeutic outcomes can enable clinicians to identify the most appropriate treatment approach for their multiple sclerosis patients. Author: Harris.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

Drug Target Review

FEBRUARY 11, 2025

These hurdles not only delay patient access to innovative treatments but also threaten the economic sustainability of research and development (R&D) and the advancement of medical innovation. These failures not only increase overall costs, but also slow down scientific progress, delaying potential treatments for patients.

Drug Development 59

Drug Development Bioinformatics Drugs Small Molecule 59

Codon

MAY 22, 2025

DNA-based methods could provide us with an early warning system that detects the presence and abundance of resistance genes, informing where and when specific antibiotics should be used. He writes about microbiology, bioinformatics, and evolution. While Calvin Jr.'s Today, there are strains of S. Cite: Blake K.

DNA 100

DNA Laboratories Doctors Production 100